Literature DB >> 1416868

In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

W A Agger1, S M Callister, D A Jobe.   

Abstract

We determined the in vitro susceptibilities of eight Borrelia burgdorferi isolates to five oral cephalosporins. MICs for B. burgdorferi 297 were 23 micrograms/ml (cephalexin), 45 micrograms/ml (cefadroxil), 91 micrograms/ml (cefaclor), 0.13 microgram/ml (cefuroxime), 0.8 microgram/ml (cefixime), and 0.02 microgram/ml (ceftriaxone). When B. burgdorferi isolates were exposed to concentrations twice the MIC of cefuroxime, cefixime, or ceftriaxone, at least 72 h of incubation was required to kill 99% of the organisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416868      PMCID: PMC192050          DOI: 10.1128/AAC.36.8.1788

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Failure of tetracycline therapy in early Lyme disease.

Authors:  R J Dattwyler; J J Halperin
Journal:  Arthritis Rheum       Date:  1987-04

2.  Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody.

Authors:  A G Barbour; S L Tessier; W J Todd
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

3.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

4.  The penetration of ceftriaxone into synovial fluid of the inflamed joint.

Authors:  J R Morgan; A Paull; M O'Sullivan; B D Williams
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

5.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

6.  New chemotherapeutic approaches in the treatment of Lyme borreliosis.

Authors:  B J Luft; D J Volkman; J J Halperin; R J Dattwyler
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

7.  Lyme disease assay which detects killed Borrelia burgdorferi.

Authors:  S M Callister; R F Schell; S D Lovrich
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

8.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin.

Authors:  R J Dattwyler; J J Halperin; D J Volkman; B J Luft
Journal:  Lancet       Date:  1988-05-28       Impact factor: 79.321

10.  Successful parenteral penicillin therapy of established Lyme arthritis.

Authors:  A C Steere; J Green; R T Schoen; E Taylor; G J Hutchinson; D W Rahn; S E Malawista
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

View more
  14 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 2.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

3.  Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry.

Authors:  Y F Liu; L C Lim; K Schell; S D Lovrich; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

4.  Development of an extrachromosomal cloning vector system for use in Borrelia burgdorferi.

Authors:  M Sartakova; E Dobrikova; F C Cabello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 5.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

6.  In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.

Authors:  R J Kazragis; L L Dever; J H Jorgensen; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

Authors:  J M Levin; J A Nelson; J Segreti; B Harrison; C A Benson; F Strle
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia burgdorferi.

Authors:  Charlene R Jackson; Julie A Boylan; Jonathan G Frye; Frank C Gherardini
Journal:  Int J Antimicrob Agents       Date:  2007-10-01       Impact factor: 5.283

10.  Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans.

Authors:  S W Luger; P Paparone; G P Wormser; R B Nadelman; E Grunwaldt; G Gomez; M Wisniewski; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.